App-Based Study of Daily Life and Treatment in IgA Nephropathy
Follows adults with IgA nephropathy, a kidney disease, through symptoms, treatments and quality of life.
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 4 Mar 2025
- Planned end
- 30 Jun 2025
- Type of study
- Observational, 4 groups
- Treatments tested
- Other treatment
- Iptacopan
- Atrasentan
- Record updated
- 17 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in the US who have IgA nephropathy, and for adult caregivers of patients with IgAN. Participants use a mobile app and read English.
- Age
- 18 years or older. Caregivers must be adults too; the patient they care for can be an adult or a child under 18.
- Sex
- All sexes can join.
- Disease stage
- Diagnosis of IgAN, regardless of symptoms or treatment history.
- Earlier treatment
- None required. Any treatment history is fine.
Main reasons for not taking part
- Not based in the US
- Cannot read and understand English
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Diagnosis of IgAN, regardless of symptom or treatment history
- Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age
- US-based with a proficient understanding of and ability to read the English language
Who cannot take part
- None
Where in United States
- Boston, MassachusettsHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
About the trial
What the trial wants to find out
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.
The 4 groups in the trial
- Immunoglobulin A nephropathy (IgAN)-Iptacopan
IgAN patients taking iptacopan and their caregivers
Treatment: Iptacopan
- IgAN-atrasentan
IgAN patients taking atrasentan and their caregivers
Treatment: Atrasentan
- IgAN-other treatment
IgAN patients taking other specific treatment and their caregivers
Treatment: Other treatment
- IgAN-no treatment
IgAN patients taking none treatment and their caregivers
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Mobile App-Based, Prospective, Observational Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
- Plain-language title
- App-Based Study of Daily Life and Treatment in IgA NephropathyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 June 2025